MedTrace Logo

Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease

NCT06056921 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-09-28

No results posted yet for this study

Summary

This is a single arm study to evaluate the efficacy and safety of CD19 targeted CAR-T cells therapy for patients with Refractory Autoimmune Disease

Conditions

  • SLE (Systemic Lupus)
  • Sjogren's Syndrome
  • Systemic Scleroderma
  • Dermatomyositis
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Interventions

BIOLOGICAL

CD19 targeted CAR-T cells

A single infusion of CD19 CAR-T cells will be administered intravenously

Sponsors & Collaborators

  • Chongqing Precision Biotech Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Liyun Zhang, M.D · Shanxi Bethune Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-31
Primary Completion
2025-12-31
Completion
2026-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06056921 on ClinicalTrials.gov